The Cost-Effectiveness of Early High-Acuity Postoperative Care for Medium-Risk Surgical Patients

被引:1
|
作者
Leaman, Esrom E. [1 ,2 ]
Ludbrook, Guy L. [1 ,2 ]
机构
[1] Royal Adelaide Hosp, Dept Anaesthesia, 3G 395,1 N Terr, Adelaide 5000, Australia
[2] Univ Adelaide, Discipline Acute Care Med, Adelaide, Australia
来源
ANESTHESIA AND ANALGESIA | 2024年 / 139卷 / 02期
关键词
SURGERY; MORTALITY; LENGTH; STAY;
D O I
10.1213/ANE.0000000000006743
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
BACKGROUND:Initiatives in perioperative care warrant robust cost-effectiveness analysis in a cost-constrained era when high-value care is a priority. A model of anesthesia-led early high-acuity postoperative care, advanced recovery room care (ARRC), has shown benefit in terms of hospital and patient outcomes, but its cost-effectiveness has not yet been formally determined.METHODS:Data from a previously published single-center prospective cohort study of ARRC in medium-risk patients were used to generate a Markov model, which described patient transition between care locations, each with different characteristics and costs. The incremental cost-effectiveness ratio (ICER), using days at home (DAH) and hospital costs, was calculated for ARRC compared to usual ward care using deterministic and probabilistic sensitivity analysis.RESULTS:The Markov model accurately described patient disposition after surgery. For each patient, ARRC provided 4.3 more DAH within the first 90 days after surgery and decreased overall hospital costs by $1081 per patient. Probabilistic sensitivity analysis revealed that ARRC had a 99.3% probability of increased DAH and a 77.4% probability that ARRC was dominant from the perspective of the hospital, with improved outcomes and decreased costs.CONCLUSIONS:Early high-acuity care for approximately 24 hours after surgery in medium-risk patients provides highly cost-effective improvements in outcomes when compared to usual ward care.
引用
下载
收藏
页码:323 / 331
页数:9
相关论文
共 50 条
  • [41] A Specialized Transplantation Critical Care Model: Expanding Liver Transplantation Access to High-Acuity Patients
    Zimmerman, M. A.
    Selim, M.
    Kim, J.
    Kozeniecki, M.
    Hong, J. C.
    TRANSPLANTATION PROCEEDINGS, 2018, 50 (09) : 2619 - 2621
  • [42] Evaluation of cost-effectiveness of early KRAS testing in high-risk recurrence colorectal cancer patients in Italy
    Pinto, Carmine
    Barone, Carlo
    Normanno, Nicola
    Cognetti, Francesco
    Falcone, Alfredo
    Capussotti, Lorenzo
    Mantovani, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] Cost-effectiveness of ramipril in preventing cardiovascular events in high-risk patients
    Ganguly, R
    Parasuraman, TV
    VALUE IN HEALTH, 2003, 6 (03) : 321 - 322
  • [44] Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy
    Aspelin, P
    Aubry, P
    Fransson, SG
    Strasser, R
    Willenbrock, R
    Lundkvist, J
    AMERICAN HEART JOURNAL, 2005, 149 (02) : 298 - 303
  • [45] COST-EFFECTIVENESS OF A POLYPILL FOR PATIENTS WITH OR AT HIGH RISK OF CARDIOVASCULAR DISEASE IN AN NHS SETTING
    Crossan, C. J.
    Dehbi, H.
    Thom, S.
    Poulter, N.
    Lord, J.
    VALUE IN HEALTH, 2017, 20 (09) : A620 - A620
  • [46] COST-EFFECTIVENESS ANALYSIS OF ALIROCUMAB IN HIGH CARDIOVASCULAR-RISK PATIENTS IN ITALY
    Povero, M.
    Pradelli, L.
    Fanelli, F.
    Gazzi, L.
    Serra, A.
    VALUE IN HEALTH, 2020, 23 : S490 - S490
  • [47] Screening for second primary melanoma in high risk patients: A cost-effectiveness analysis
    Seth, Divya
    Krasne, Margaret
    James, Lyndon
    Kim, Jane
    Bordeaux, Jeremy
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB2 - AB2
  • [48] Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: A Swiss perspective
    Sendi, P
    Russ, W
    Battegay, E
    Bucher, H
    VALUE IN HEALTH, 2004, 7 (06) : 693 - 693
  • [49] Cost-effectiveness analysis of alirocumab in high cardiovascular-risk patients in Italy
    Povero, Massimiliano
    Pradelli, Lorenzo
    Serra, Andrea
    Fanelli, Francesca
    Gazzi, Luca
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2021, 22 (01)
  • [50] Cost-effectiveness of interferon for high-risk (stage III) melanoma patients
    Guillem, V
    Alvarez-Mon, M
    Camacho, F
    Diaz-Perez, JL
    Diaz-Rubio, E
    Gonzalez-Larriba, JL
    Lopez-Lopez, JJ
    Moreno, JA
    Serrano, S
    Toribio, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S372 - S372